In prostate cancer patients who undergo chemical castration therapy, testosterone levels are suddenly and drastically reduced, resulting in increased fat deposition, increased insulin levels, impaired insulin sensitivity, and increased risk of diabetes and MetS classification [32,33]. This evidence concerns the gene INS and metabolic syndrome.